Table 1. Overview of T-cell responses against three cryptic epitopes in healthy subjects and melanoma, breast carcinoma, and renal cell carcinoma patients.

	AIM2	NA17-A nonamer	NA17-A decamer
Melanoma	6/13 (46%)	6/16 (38%)	6/16 (38%)
Breast cancer	0/9 (0%)*	0/7 (0%)	0/7 (0%)>
Renal cell carcinoma	0/4 (0%)	0/4 (0%)	0/4 (0%)
Healthy donors	0/13 (0%)*	0/15 (0%)*	0/15 (0%)*

^*P < 0.05 (Fisher’s exact test), as compared with melanoma patients.